Q-omics provides the consensus-scored MPHOSPH6 profile across patient tissues and cancer cell-line models. MPHOSPH6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MPHOSPH6 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, MPHOSPH6 protein abundance shows 25,566 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, HNSC, and GBM as cancer lineages where MPHOSPH6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MPHOSPH6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MPHOSPH6 survival associations across molecular data types. MPHOSPH6 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MPHOSPH6 RNA expression–survival associations across cancer types. High MPHOSPH6 expression shows unfavorable associations in LIHC, HNSC, SARC, LUAD and ACC, but favorable associations in OV. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MPHOSPH6 RNA expression.
This table summarizes MPHOSPH6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MPHOSPH6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MPHOSPH6 shows higher tumor expression in HNSC, LIHC, STAD, KIRP, BLCA and COAD. The HNSC box plot shows higher MPHOSPH6 RNA expression in tumor versus normal tissue (log2 FC = +0.724, t-test p < 0.001).
This table shows molecular features associated with MPHOSPH6 in patient tissues and cancer cell lines. In patient samples, MPHOSPH6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MPHOSPH6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
